The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer

Ansari, Rokaya; Craze, Madeleine L; Alfarsi, Lutfi; Masisi, Brendah K; Ellis, Ian O; Rakha, Emad A; Green, Andrew R

Abstract

Purpose: Breast cancer (BC) is a heterogeneous disease consisting of various subtypes, with
different prognostic and therapeutic outcomes. The amino acid transporter, SLC7A8, is over expressed in estrogen receptor positive BC. However the consequences of this overexpression, it terms of disease prognosis, is still obscure. This study aimed to evaluate the biological and prognostic value of SLC7A8 in BC with emphasis on the intrinsic molecular subtypes.
Methods: SLC7A8 was assessed at the genomic, using METABRIC data (n=1,980), and proteomic, using immunohistochemistry and TMA (n=1,562), levels in well-characterised primary BC cohorts. SLC7A8 expression was examined with clinicopathological parameters, molecular subtypes, and patient outcome.
Results: SLC7A8 mRNA and SLC7A8 protein expression were strongly associated with good prognostic features, including small tumour size, low tumour grade and good Nottingham Prognostic Index (NPI) (all P

Citation

Ansari, R., Craze, M. L., Alfarsi, L., Masisi, B. K., Ellis, I. O., Rakha, E. A., & Green, A. R. (2020). The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer. Breast Cancer Research and Treatment, 181(1), 1-12. https://doi.org/10.1007/s10549-020-05586-6

• Journal Article Type: Article
• Acceptance Date: Feb 28, 2020
• Online Publication Date: Mar 21, 2020
• Publication Date: 2020-05
• Deposit Date: Feb 28, 2020
• Publicly Available Date: Mar 22, 2021
• Journal: Breast Cancer Research and Treatment
• Print ISSN: 0167-6806
• Electronic ISSN: 1573-7217
• Publisher: Springer Verlag
• Peer Reviewed: Peer Reviewed
• Volume: 181
• Issue: 1
• Pages: 1-12
• DOI: https://doi.org/10.1007/s10549-020-05586-6
• Keywords: Cancer Research; Oncology
• Public URL: https://nottingham-repository.worktribe.com/output/4049853
• Publisher URL: https://link.springer.com/article/10.1007/s10549-020-05586-6
• Additional Information: Received: 24 October 2019; Accepted: 29 February 2020; First Online: 21 March 2020; : ; : The authors declare that they have no conflict of interest.; : This study was approved by the Nottingham Research Ethics Committee 2 under the title ‘Development of a molecular genetic classification of breast cancer’ and the North West—Greater Manchester Central Research Ethics Committee under the title ‘Nottingham Health Science Biobank (NHSB)’ reference number 15/NW/0685. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Release of data were also pseudoanonymised as per the UK Human Tissue Act regulations. This article does not contain any studies with animals performed by any of the authors.; : All tissue samples from Nottingham used in this study were pseudoanonymised and collected prior to 1st September 2006; therefore under the UK Human Tissue Act informed patient consent was not needed.